combination therapies outperforming semaglutide A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the Semaglutide and Tirzepatide Lead the

The medication is HSA/FSA eligible and available in all 50 states without insurance or membership fees

Misdiagnosis is not uncommon: Some 40 percent of adults with type 1 diabetes are initially misdiagnosed with type 2 diabetes, for example

The primary endpoint was change in body weight during the maintenance period

Theyve been designed to be taken alongside lifestyle changes that will enable you to eventually come off the medications and maintain your lower weight for the long term

2020;4(5):bvaa037

Benefits of Ozempic & Wegovy (Semaglutide) Reduced appetite and fewer cravings Improved portion control Gradual, medically supervised weight loss Potential improvement in metabolic markers Support for long-term lifestyle changes Individual results vary